Cargando…

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma

PURPOSE: High-dose pegylated interferon α-2b (peginterferon α-2b) significantly decreased disease recurrence in patients with resected stage III melanoma in a clinical study. We investigated the pharmacokinetics (PK) and safety of high-dose peginterferon α-2b in patients with high-risk melanoma. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daud, A. I., Xu, C., Hwu, W.-J., Urbas, P., Andrews, S., Papadopoulos, N. E., Floren, L. C., Yver, A., DeConti, R. C., Sondak, V. K.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2010
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3043235/ https://www.ncbi.nlm.nih.gov/pubmed/20509027 http://dx.doi.org/10.1007/s00280-010-1326-9

Ejemplares similares

Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma
por: DeConti, R C, et al.
Publicado: (2010)

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
por: Algazi, A P, et al.
Publicado: (2012)

Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma
por: Jia, Dong-Dong, et al.
Publicado: (2021)

Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review
por: Okuyama, Sonia, et al.
Publicado: (2010)

Phase I study of pegylated interferon‐alpha‐2b as an adjuvant therapy in Japanese patients with malignant melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2016)

Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study
por: García-García, Idrian, et al.
Publicado: (2010)

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
por: Wu, Huali, et al.
Publicado: (2015)

Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers
por: Costa, Marisa Boff, et al.
Publicado: (2018)

Adjuvant interferon in the treatment of melanoma
por: Middleton, M R
Publicado: (1999)

Adjuvant interferon in the treatment of melanoma
por: Kirkwood, J M
Publicado: (2000)

Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase
por: Modi, Tapasvi, et al.
Publicado: (2021)

Long-term pegylated interferon-α and its potential in the treatment of melanoma
por: Dummer, Reinhard, et al.
Publicado: (2009)

Influence of Surface-Modification via PEGylation or Chitosanization of Lipidic Nanocarriers on In Vivo Pharmacokinetic/Pharmacodynamic Profiles of Apixaban
por: Zaky, Mohamed F., et al.
Publicado: (2023)

Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon
por: Gogas, Helen, et al.
Publicado: (2010)

Adjuvant interferon in melanoma – a resurrection?
por: Middleton, M R, et al.
Publicado: (2001)

Adjuvant interferon in the treatment of melanoma – reply
por: Middleton, M R
Publicado: (2000)

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]
Publicado: (2019)

Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria
por: Qi, Yulan, et al.
Publicado: (2021)

Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma
por: Salans, Mia, et al.
Publicado: (2021)

Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib
por: Liao, Mingxiang, et al.
Publicado: (2022)

Pharmacokinetic Characteristics, Pharmacodynamic Effect and In Vivo Antiviral Efficacy of Liver-Targeted Interferon Alpha
por: Rycroft, Daniel, et al.
Publicado: (2015)

Saturable human neopterin response to interferon-α assessed by a pharmacokinetic-pharmacodynamic model
por: Jeon, Sangil, et al.
Publicado: (2013)

Adjuvant therapy of melanoma with interferon: lessons of the past decade
por: Ascierto, Paolo A, et al.
Publicado: (2008)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Early Treatment with Pegylated Interferon Lambda for Covid-19
por: Reis, Gilmar, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
por: Bruin, Maaike A. C., et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of CSL112
por: Ortega-Paz, Luis, et al.
Publicado: (2023)

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2015)

Correction: Pharmacokinetic Characteristics, Pharmacodynamic Effect and In Vivo Antiviral Efficacy of Liver-Targeted Interferon Alpha
Publicado: (2015)

Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial
por: Laffel, L. M. B., et al.
Publicado: (2018)

Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
por: Meyer, Douglas F., et al.
Publicado: (2010)

Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B
por: Zheng, Caixia, et al.
Publicado: (2019)

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab‐Treated Advanced Melanoma
por: Chatterjee, MS, et al.
Publicado: (2016)

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
por: Balakirouchenane, David, et al.
Publicado: (2020)

Adjuvant interferon alpha 2b in high risk melanoma – the Scottish study
por: Cameron, D A, et al.
Publicado: (2001)

Pharmacokinetics and Pharmacodynamics of Clofazimine for Treatment of Cryptosporidiosis
por: Zhang, Cindy X., et al.
Publicado: (2022)

The Pharmacokinetics and Pharmacodynamics of Iron Preparations
por: Geisser, Peter, et al.
Publicado: (2011)

Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
por: Chen, Nianhang, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8dr3gf8hked0uf5sckrjaul1a7